Home Cart Sign in  
Chemical Structure| 432001-19-9 Chemical Structure| 432001-19-9

Structure of C188-9
CAS No.: 432001-19-9

Chemical Structure| 432001-19-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

C188-9 is a STAT3 inhibitor and has no effects on non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) in mice.

Synonyms: TTI-101

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of C188-9

CAS No. :432001-19-9
Formula : C27H21NO5S
M.W : 471.52
SMILES Code : O=S(C1=CC=C(OC)C=C1)(NC2=C3C=CC=CC3=C(O)C(C4=C5C=CC=CC5=CC=C4O)=C2)=O
Synonyms :
TTI-101
MDL No. :MFCD03141581
InChI Key :QDCJDYWGYVPBDO-UHFFFAOYSA-N
Pubchem ID :1324494

Safety of C188-9

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of C188-9

JAK-STAT

Isoform Comparison

Biological Activity

Target
  • STAT3

    STAT3, Kd:4.7 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
BEL-7404 cells 1μM To evaluate the inhibitory effect of C188-9 on STAT3 phosphorylation, results showed that C188-9 significantly attenuated Prrx1 knockdown-mediated cell migration, drug resistance, and expression of stem cell markers. PMC6873584
JAK2V617F macrophages 5 µM Inhibition of STAT3 significantly decreased the production of IL-6 PMC7897702
Huh7 0.19 to 100 μM 48 hours C188-9 significantly reduced the viability of Huh7 cells with an IC50 value of 11.27 μM. PMC5873583
PLC/PRF/5 0.19 to 100 μM 48 hours C188-9 significantly reduced the viability of PLC/PRF/5 cells with an IC50 value of 10.19 μM. PMC5873583
HepG2 0.19 to 100 μM 48 hours C188-9 significantly reduced the viability of HepG2 cells with an IC50 value of 11.83 μM. PMC5873583

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice T cell transfer colitis model Intraperitoneal injection 2.5 μM 10 minutes before ischemia and during the first 10 minutes of reperfusion C188-9 significantly alleviated the severity of colitis in the eEF2K KO group but did not affect the severity of the disease in the WT group. PMC10598003
mice T cell transfer colitis model intraperitoneal injection 75 mg/kg Twice daily for 2 to 3 weeks C188-9 treatment significantly alleviated the severity of colitis in the eEF2K KO group, indicating that C188-9 regulates inflammatory responses by inhibiting the STAT3 pathway. PMC10598003
mice Hep Pten- mice intraperitoneal injection 50mg/kg once daily for 2 months C188-9 significantly inhibited tumor growth in Hep Pten- mice and improved the pathological lesions of NASH. PMC5873583
Mice Bile duct ligation (BDL)-induced liver fibrosis model Intraperitoneal injection 30 mg/kg/day daily C188-9 significantly reduced BDL-induced liver fibrosis, as evidenced by down-regulation of pro-fibrogenic genes (e.g., collagen type I, collagen type III, and α-SMA), reduced hepatic hydroxylproline levels, and decreased histological evidence of liver fibrosis PMC6881349

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06141031 Pancreatic Cancer PHASE1|PHASE2 SUSPENDED 2025-09-28 University of Colorado, Aurora... More >>, Colorado, 80045, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.12mL

0.42mL

0.21mL

10.60mL

2.12mL

1.06mL

21.21mL

4.24mL

2.12mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories